Pacira BioSciences, Inc.
PCRXNasdaq
$25.61
↑ +0.0%Jul 17 close · end-of-day
Price
1Y↑ +13.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.0B
Enterprise Value
$1.2B
P/E
197.0
P/S
1.4
P/B
1.6
EV/EBITDA
10.5
PEG
—
FCF Yield
12.7%
Dividend Yield
—
Revenue (TTM)
$734.9M
Net Income (TTM)
$5.1M
Free Cash Flow (TTM)
$132.7M
Gross Margin
—
Operating Margin
3.3%
Net Margin
0.7%
ROE
0.8%
ROIC
1.5%
Debt / Equity
0.6
Net Cash
-$165.5M
Return 1Y
+14.9%
Company profile
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectionable suspension. iovera system produces controlled doses of cold temperature only to targeted nerves.
- CEO
- David M. Stack
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 720
- Headquarters
- Florida
- Website
- pacira.com
Management & directors
- Riker Lauren BullaroSenior Vice President, Finance
- Williams Kristen MarieChief Administrative Officer
- Slonin JonathanChief Medical Officer
- Cross ShawnChief Financial Officer
- Lee Frank D.Chief Executive Officer
- Teehan BrendanChief Commercial Officer
Roles derived from SEC Form 4 filings.
Earnings
PCRX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$177.4M↑ +5.0%
Diluted EPS$0.07↓ -30.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $429.6M | $541.5M | $666.8M | $675.0M | $701.0M | $726.4M |
| Gross profit | — | — | — | — | — | — |
| Operating income | $46.4M | $89.9M | $60.0M | $87.7M | -$73.4M | $19.2M |
| Net income | $145.5M | $42.0M | $15.9M | $42.0M | -$99.6M | $7.0M |
| Diluted EPS | $3.33 | $0.92 | $0.34 | $0.89 | -$2.15 | $0.16 |
| Operating cash flow | $77.0M | $125.7M | $145.3M | $154.6M | $189.4M | $152.0M |
| Free cash flow | $39.2M | $79.9M | $115.2M | $139.5M | $178.8M | $136.7M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 10.8% | 16.6% | 9.0% | 13.0% | -10.5% | 2.6% |
| Net margin | 33.9% | 7.8% | 2.4% | 6.2% | -14.2% | 1.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $178.0M | $168.6M | $187.3M | $168.9M | $181.1M | $179.5M | $196.9M | $177.4M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $28.2M | -$139.5M | $24.7M | $2.0M | $8.5M | $6.4M | $2.3M | $6.9M |
| Net income | $18.9M | -$143.5M | $16.0M | $4.8M | -$4.8M | $5.4M | $1.6M | $2.9M |
| Diluted EPS | $0.39 | -$3.11 | $0.38 | $0.10 | -$0.11 | $0.12 | $0.05 | $0.07 |
| Operating cash flow | $53.2M | $53.9M | $33.1M | $35.5M | $12.0M | $60.8M | $43.7M | $25.7M |
| Free cash flow | $51.6M | $49.8M | $31.0M | $26.9M | $9.3M | $57.0M | $43.5M | $23.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 15.9% | -82.8% | 13.2% | 1.2% | 4.7% | 3.5% | 1.2% | 3.9% |
| Net margin | 10.6% | -85.1% | 8.5% | 2.8% | -2.7% | 3.0% | 0.8% | 1.6% |
Company news
Jul 2, 2026
Jul 1, 2026
Jun 30, 2026
- 20d agoUpdate: S&P 500, Nasdaq Composite Close Strongest Quarter in Six Years Amid Gains in Technology, Decline in Crude Oilfinance.yahoo.com
- 20d agoSector Update: Healthcare Stocks Softer Late Afternoonfinance.yahoo.com
- 20d agoTop Midday Declinersfinance.yahoo.com
- 20d agoUpdate: US Equity Indexes Rise as Semiconductors Lift Technology; Crude Oil Slips as Trump's Envoys in Qatar for Indirect Talksfinance.yahoo.com
- 20d agoPacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biometfinance.yahoo.com
- 20d agoZimmer to buy Pacira pain relief device for up to $140Mmedtechdive.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-11 | Riker Lauren Bullaro· Senior Vice President, Finance | Sale | 6,115 | $23.50 | $143,702.50 | filing |
| 2026-06-10 | Hirawat Samit | Award | 6,405 | $0.00 | $0.00 | filing |
| 2026-06-10 | CHRISTIE CHRISTOPHER | Award | 6,405 | $0.00 | $0.00 | filing |
| 2026-06-10 | Young Alethia | Award | 6,405 | $0.00 | $0.00 | filing |
| 2026-06-10 | YANG MICHAEL J. | Award | 6,405 | $0.00 | $0.00 | filing |
| 2026-06-10 | BIGAL MARCELO | Award | 6,405 | $0.00 | $0.00 | filing |
| 2026-06-10 | Froimson Mark | Award | 6,405 | $0.00 | $0.00 | filing |
| 2026-06-10 | Brege Laura | Award | 6,405 | $0.00 | $0.00 | filing |
| 2026-06-04 | Williams Kristen Marie· Chief Administrative Officer | Sale | 10,259 | $22.27 | $228,467.93 | filing |
| 2026-06-03 | Williams Kristen Marie· Chief Administrative Officer | Tax withholding | 8,528 | $22.32 | $190,344.96 | filing |
| 2026-06-03 | SLONIN JONATHAN· Chief Medical Officer | Tax withholding | 4,728 | $22.32 | $105,528.96 | filing |
| 2026-06-03 | Riker Lauren Bullaro· Senior Vice President, Finance | Tax withholding | 3,187 | $22.32 | $71,133.84 | filing |
| 2026-04-23 | Cross Shawn· Chief Financial Officer | Sale | 12,941 | $25.16 | $325,595.56 | filing |
| 2026-04-23 | Cross Shawn· Chief Financial Officer | Option exercise | 12,941 | $16.45 | $212,879.45 | filing |
| 2026-04-22 | Cross Shawn· Chief Financial Officer | Sale | 1,500 | $25.01 | $37,515.00 | filing |
| 2026-04-22 | Cross Shawn· Chief Financial Officer | Option exercise | 1,500 | $16.45 | $24,675.00 | filing |
| 2026-04-21 | Cross Shawn· Chief Financial Officer | Sale | 2,845 | $25.01 | $71,153.45 | filing |
| 2026-04-21 | Cross Shawn· Chief Financial Officer | Option exercise | 2,845 | $16.45 | $46,800.25 | filing |
| 2026-04-20 | Cross Shawn· Chief Financial Officer | Sale | 7,714 | $25.14 | $193,929.96 | filing |
| 2026-04-20 | Cross Shawn· Chief Financial Officer | Option exercise | 7,714 | $16.45 | $126,895.30 | filing |
| 2026-03-17 | SLONIN JONATHAN· Chief Medical Officer | Sale | 3,261 | $22.82 | $74,416.02 | filing |
| 2026-03-17 | Froimson Mark | Sale | 500 | $21.81 | $10,905.00 | filing |
| 2026-02-11 | Lee Frank D.· Chief Executive Officer | Award | 261,818 | $0.00 | $0.00 | filing |
| 2026-02-11 | Cross Shawn· Chief Financial Officer | Award | 49,091 | $0.00 | $0.00 | filing |
| 2026-02-11 | Williams Kristen Marie· Chief Administrative Officer | Award | 54,546 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.